A kind of medicine composition for treating cold and preparation method thereof

Abstract

The present invention relates to the technical field of traditional Chinese medicines, and specifically discloses a pharmaceutical composition for treating a cold and a preparation method thereof, wherein the pharmaceutical composition comprises, by weight, 10-20 parts of acetaminophen, 0.5-0.9 parts of loratadine, 240-330 parts of herba phyllanthi, 320-420 parts of herba chelidonii and 100-150 parts of herba xanthium. The pharmaceutical composition of the present invention can effectively treat various types of colds, including influenza virus, cold-type cold and heat-type cold, effectively relieve fever, prevent and treat influenza virus, and will not cause side effects of drowsiness and loss of appetite, and has a definite curative effect through the combination of traditional Chinese medicine extracts and western medicines.

Description

Technical Field

[0001] The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a medicinal composition for treating colds and a preparation method thereof. Background Art

[0002] Cold is a common acute upper respiratory tract viral infectious disease, with main clinical manifestations such as nasal congestion, runny nose, sneezing, headache, aversion to cold, fever, and general malaise. Cold is caused by exogenous pathogens such as wind and cold or due to improper seasons. Cold is a common and frequently-occurring disease that can occur all year round, mostly in winter and spring. Although mild colds can be cured without medication, severe colds can affect work and life, and even endanger the lives of children and the elderly. Especially when the epidemic cold breaks out, it spreads rapidly, infects many people, has severe symptoms, and even leads to death, causing serious consequences. Moreover, colds are also factors that cause and aggravate many diseases such as cough, palpitations, edema, and arthritis. Therefore, active prevention and treatment of colds is required.

[0003] At present, Chinese medicine has a good therapeutic effect on colds. For example, Chinese patent CN113144164A discloses a Chinese medicine composition and preparation for treating gastrointestinal colds, wherein the Chinese medicine composition comprises the following raw materials: Atractylodes lancea, dried orange peel, Magnolia bark, Poria cocos, Pilosula ovata, loquat flower, raw Pinellia ternata, ginger, Angelica dahurica, licorice extract, Patchouli oil and Perilla leaf oil; the preparation comprises the Chinese medicine composition; the invention selects Atractylodes lancea, dried orange peel, Magnolia bark, Poria cocos, Pilosula ovata, loquat flower, raw Pinellia ternata, ginger, Angelica dahurica, licorice extract, Patchouli oil and Perilla leaf oil as raw materials, and through the compounding of active components of each raw material, it has the effects of dispelling dampness, regulating qi and harmonizing the middle, and can be used for colds caused by exogenous wind-cold, internal injury and dampness stagnation or summer injury and summer heat dampness. At the same time, it was found that when the mass ratio of loquat flower, big belly peel and angelica is 1:1.3-1.5:1.2-1.3, it has good anti-inflammatory and antidiarrheal effects. However, the Chinese medicine composition only has a therapeutic effect on gastrointestinal colds, and it is difficult to quickly and completely treat all types of colds. In addition, the raw materials required are numerous and the preparation process is complicated.

[0004] Cold medicines in Western medicine are mostly quick-acting medicines, which are mainly effective for relieving cold symptoms through antiviral, heat-clearing and detoxifying approaches. For example, Chinese patent application CN106420800A discloses a Western medicine composition for treating colds, wherein the main raw materials of the Western medicine composition for treating colds are: 10-20 parts of acetaminophen, 10-20 parts of pseudoephedrine hydrochloride, 2-4 parts of artemisinin, 1-3 parts of spironolactone, 1-2 parts of dextrin, 0.5-0.8 parts of ATP, 0.9-1.7 parts of piperacillin, 0.1-0.5 parts of ampicillin, 0.1-0.2 parts of magnesium stearate, 4-6 parts of starch, and 0.1-0.4 parts of sodium bicarbonate. The invented medicine has antiviral and immune-promoting disease-resistance capabilities, thereby achieving the purpose of comprehensive rehabilitation, treating both the symptoms and the root causes, short course of treatment, quick effect, small toxic and side effects, and very low cost. However, the western medicine combination can easily cause drug resistance in people, and after taking the medicine, it is easy to cause adverse symptoms such as drowsiness and loss of appetite, and the side effects are relatively large.

[0005] Therefore, there is a need for a composition that can be used for treating colds, requires few raw materials, has good therapeutic effects and has no side effects. Summary of the invention

[0006] As used herein, the singular forms "a," "an," and "the" include both singular and plural referents unless the context clearly dictates otherwise. Numerical ranges recited by endpoints include all numbers and fractions within the corresponding ranges, as well as the recited endpoints.

[0007] The present invention aims at solving the problems in the prior art and provides a pharmaceutical composition for treating colds and a preparation method thereof. The pharmaceutical composition is made of Chinese herbal extracts and western medicines, has significant therapeutic effects on relieving fever and preventing and treating influenza viruses, and does not cause side effects such as drowsiness and loss of appetite.

[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:

[0009] The invention provides a medicinal composition for treating colds, which comprises, by weight, 10-20 parts of acetaminophen, 0.5-0.9 parts of loratadine, 240-330 parts of physalis, 320-420 parts of chelidonium and 100-150 parts of xanthium.

[0010] Preferably, the pharmaceutical composition comprises, by weight, 10-20 parts of acetaminophen, 0.5-0.8 parts of loratadine, 280-330 parts of physalis, 320-350 parts of chelidonium and 100-120 parts of xanthium.

[0011] Further preferably, the pharmaceutical composition comprises, by weight, 20 parts of acetaminophen, 0.8 parts of loratadine, 280 parts of phytoncidum, 320 parts of chelidonium and 100 parts of xanthium.

[0012] Preferably, the mass ratio of the herbaceous physalis, herbaceous physalis and acetaminophen is 25-33:32-38:2.

[0013] The present invention also provides a method for preparing the above-mentioned pharmaceutical composition, comprising the following steps:

[0014] S1, taking the formulated amount of Herba Lycopodii, Herba Lycopodii and Herba Xanthium, adding 1,3-butanediol, adjusting the pH, performing ultrasonic extraction, then filtering, and removing 1,3-butanediol by rotary evaporation to obtain an alcohol extract;

[0015] S2, adding ultrapure water to the alcohol-extracted physalis, physalis scabra and Xanthium sibiricum for ultrasonic extraction, and then filtering to obtain a water extract;

[0016] S3, combining the alcohol extract and the water extract, concentrating under reduced pressure to obtain a concentrate, and freeze-drying to obtain a Chinese medicine powder;

[0017] S4. Then, the acetaminophen and loratadine in the formula amount are crushed separately and then mixed, and the above-mentioned Chinese medicine powder is added and mixed evenly to obtain a pharmaceutical composition.

[0018] Preferably, in step S1, the material-liquid ratio of the total mass of the Herba Lycopodii, Herba Eupatorii and Herba Xanthium to 1,3-butanediol is 1 g: 5-8 ml; and the concentration of the 1,3-butanediol is 70%-80%.

[0019] Further preferably, in step S1, the solid-liquid ratio of the total mass of the Herba Lycopodiellae, Herba Eupatorii and Herba Xanthium to 1,3-butanediol is 1 g: 6-8 ml.

[0020] Most preferably, the solid-liquid ratio of the total mass of the Herba Lycopodii, Herba Eupatorii and Herba Xanthium to 1,3-butanediol in step S1 is 1 g:6 ml.

[0021] Preferably, the pH in step S1 is 4-6; the conditions for ultrasonic extraction in step S1 are: temperature 40-45° C., extraction times 1-3 times, and each ultrasonic extraction time 5-8 min.

[0022] Preferably, in step S2, the material-liquid ratio of the total mass of the Herba Lycopodiellae, Herba Lycopodiellae and Herba Xanthium sibiricum after alcohol extraction to ultrapure water is 1 g: 8-10 ml.

[0023] Further preferably, in step S2, the material-liquid ratio of the total mass of the Herba Lycopodiellae, Herba Lycopodiellae and Herba Xanthium after alcohol extraction to ultrapure water is 1 g: 8-9 ml.

[0024] Most preferably, the material-liquid ratio of the total mass of the Herba Lycopodiellae, Herba Lycopodiellae and Herba Xanthium after alcohol extraction in step S2 to ultrapure water is 1 g:9 ml.

[0025] Preferably, the conditions for the ultrasonic extraction in step S2 are: temperature 20-25° C., time 10-15 min.

[0026] The present invention also provides use of the above-mentioned pharmaceutical composition or the pharmaceutical composition prepared by the above-mentioned preparation method in preparing medicine for treating colds.

[0027] Compared with the prior art, the present invention has the following beneficial effects:

[0028] The pharmaceutical composition of the present invention can effectively treat various types of colds (including influenza virus, wind-cold type cold and wind-heat type cold) by combining traditional Chinese medicine extracts with western medicine, can effectively relieve fever, prevent and treat influenza virus, and will not cause side effects of drowsiness and loss of appetite. DETAILED DESCRIPTION

[0029] The present invention is described below through specific embodiments to make the technical solution of the present invention easier to understand and grasp, but the present invention is not limited thereto, and the described embodiments are only a part of the embodiments of the present invention, rather than all of the embodiments.

[0030] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0031] Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention. The experimental methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials described are commercially available unless otherwise specified.

[0032] Basic Example 1 A pharmaceutical composition for treating colds

[0033] The composition is composed of 20 parts of acetaminophen, 0.8 parts of loratadine, 280 parts of phytoncides, 320 parts of chelidonium and 100 parts of xanthium.

[0034] Basic Example 2 A pharmaceutical composition for treating colds

[0035] The composition is composed of 10 parts of acetaminophen, 0.9 parts of loratadine, 240 parts of phytoncidum, 420 parts of chelidonium and 150 parts of xanthium.

[0036] Basic Example 3 A pharmaceutical composition for treating colds

[0037] By weight, the composition comprises 20 parts of acetaminophen, 0.5 parts of loratadine, 330 parts of phytoncides, 350 parts of chelidonium and 120 parts of xanthium.

[0038] Basic Example 4 A pharmaceutical composition for treating colds

[0039] Calculated by weight, the composition comprises 16 parts of acetaminophen, 0.8 parts of loratadine, 264 parts of phytoncidum, 320 parts of chelidonium and 100 parts of xanthium.

[0040] Example 1

[0041] According to the formulation of Basic Example 1, the preparation method of the pharmaceutical composition for treating colds is as follows:

[0042] (1) Alcohol extraction: Take the formulated amount of Herba Lycopodii, Herba Lycopodii and Herba Xanthium, add 70% 1,3-butanediol with a solid-liquid ratio of 1 g:6 ml, adjust the pH to 5, and perform ultrasonic extraction (ultrasonic conditions: temperature 45°C, extraction times 3 times, each ultrasonic extraction time 6 min), then filter and remove ethanol by rotary evaporation to obtain an alcohol extract;

[0043] (2) Water extraction: add ultrapure water with a solid-liquid ratio of 1 g:9 ml to the alcohol-extracted physalis, physalis scabra and Xanthium sibiricum, perform ultrasonic extraction for 12 min at 25 °C, and then filter to obtain a water extract;

[0044] (3) combining the alcohol extract and the water extract, concentrating under reduced pressure to obtain a concentrate, and freeze-drying to obtain a Chinese medicine powder; (4) then crushing the formulated amounts of acetaminophen and loratadine separately, mixing them, adding the above Chinese medicine powder and mixing them evenly to obtain a pharmaceutical composition.

[0045] Example 2

[0046] According to the formulation of Basic Example 2, the preparation method of the pharmaceutical composition for treating colds is as follows:

[0047] (1) Alcohol extraction: Take the formulated amount of Herba Lycopodii, Herba Lycopodii and Herba Xanthium, add 80% 1,3-butanediol with a solid-liquid ratio of 1 g:5 ml, adjust the pH to 4, and perform ultrasonic extraction (ultrasonic conditions: temperature 40°C, extraction times 3 times, each ultrasonic extraction time 5 min), then filter and remove ethanol by rotary evaporation to obtain an alcohol extract;

[0048] (2) Water extraction: add ultrapure water with a solid-liquid ratio of 1 g:8 ml to the alcohol-extracted physalis, physalis scabra and Xanthium sibiricum, perform ultrasonic extraction for 10 min at 20°C, and then filter to obtain a water extract;

[0049] (3) combining the alcohol extract and the water extract, concentrating under reduced pressure to obtain a concentrate, and freeze-drying to obtain a Chinese medicine powder;

[0050] (4) Then, the acetaminophen and loratadine in the prescribed amount are crushed and mixed respectively, and then added to the above-mentioned Chinese medicine powder and mixed evenly to obtain a pharmaceutical composition.

[0051] Example 3

[0052] According to the formulation of Basic Example 3, the preparation method of the pharmaceutical composition for treating colds is as follows:

[0053] (1) Alcohol extraction: Take the formulated amount of Herba Lycopodii, Herba Lycopodii and Herba Xanthium, add 70% 1,3-butanediol with a solid-liquid ratio of 1 g:8 ml, adjust the pH to 6, and perform ultrasonic extraction (ultrasonic conditions: temperature 42°C, extraction times 1 time, each ultrasonic extraction time 8 min), then filter and remove ethanol by rotary evaporation to obtain an alcohol extract;

[0054] (2) Water extraction: add ultrapure water with a solid-liquid ratio of 1 g:10 ml to the alcohol-extracted physalis, physalis scabra and Xanthium sibiricum, perform ultrasonic extraction for 15 min at 20°C, and then filter to obtain a water extract;

[0055] (3) combining the alcohol extract and the water extract, concentrating under reduced pressure to obtain a concentrate, and freeze-drying to obtain a Chinese medicine powder;

[0056] (4) Then, the acetaminophen and loratadine in the prescribed amount are crushed and mixed respectively, and then added to the above-mentioned Chinese medicine powder and mixed evenly to obtain a pharmaceutical composition.

[0057] Example 4

[0058] According to the formula of basic example 4, the preparation method of the pharmaceutical composition for treating colds is as follows:

[0059] (1) Alcohol extraction: Take the formulated amount of Herba Lycopodii, Herba Lycopodii and Herba Xanthium, add 70% 1,3-butanediol with a solid-liquid ratio of 1 g:6 ml, adjust the pH to 5, and perform ultrasonic extraction (ultrasonic conditions: temperature 45°C, extraction times 3 times, each ultrasonic extraction time 6 min), then filter and remove ethanol by rotary evaporation to obtain an alcohol extract;

[0060] (2) Water extraction: add ultrapure water with a solid-liquid ratio of 1 g:9 ml to the alcohol-extracted physalis, physalis scabra and Xanthium sibiricum, perform ultrasonic extraction for 12 min at 25 °C, and then filter to obtain a water extract;

[0061] (3) combining the alcohol extract and the water extract, concentrating under reduced pressure to obtain a concentrate, and freeze-drying to obtain a Chinese medicine powder; (4) then crushing the formulated amounts of acetaminophen and loratadine separately, mixing them, adding the above Chinese medicine powder and mixing them evenly to obtain a pharmaceutical composition.

[0062] Comparative Example 1 A pharmaceutical composition for treating colds

[0063] Compared with Example 1, the only difference is:

[0064] The preparation method is the same as that in Example 1. ...

[0065] Comparative Example 2 A pharmaceutical composition for treating colds

[0066] Compared with Example 1, the only difference is that, by weight, the pharmaceutical composition comprises 20 parts of acetaminophen, 0.8 parts of loratadine, 280 parts of Vitis amurensis, 320 parts of Eleutherodactyla scabra and 100 parts of Xanthium sibiricum. The preparation method is the same as that of Example 1.

[0067] Comparative Example 3: A pharmaceutical composition for treating colds

[0068] Compared with Example 1, the formula is the same, and the only difference is the preparation method.

[0069] (1) Take the formulated amount of Herba Lycopodii, Herba Lycopodii and Herba Xanthium, add ultrapure water with a solid-liquid ratio of 1 g:9 ml, perform ultrasonic extraction for 12 min at a temperature of 25° C., and then perform suction filtration to obtain a water extract;

[0070] (2) adding 10% 1,3-butanediol at a solid-liquid ratio of 1 g:6 ml to the water-extracted physalis, physalis and Xanthium sibiricum, adjusting the pH to 5, and performing ultrasonic extraction (ultrasonic conditions: temperature 45°C, extraction times 3 times, each ultrasonic extraction time 6 min), then filtering, and rotary evaporating to remove ethanol to obtain an alcohol extract;

[0071] (3) combining the alcohol extract and the water extract, concentrating under reduced pressure to obtain a concentrate, and freeze-drying to obtain a Chinese medicine powder; (4) then crushing the formulated amounts of acetaminophen and loratadine separately, mixing them, adding the above Chinese medicine powder and mixing them evenly to obtain a pharmaceutical composition.

[0072] Effect Example 1 Study on the therapeutic effect of the drug composition on rats with fever caused by cold

[0073] Take male Wistar rats (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.), 180-200g, adapt to feeding for 4 days, measure rectal temperature twice a day, measure continuously for 3 days, select rats with body temperature of 36.6℃-38.3℃, and body temperature change of no more than 0.3℃, and randomly divide them into blank group, model group, embodiment 1-4 group, comparative example 1-3 group, 10 rats in each group. Embodiment 1-4 group and comparative example 1-3 group were respectively gavaged with 65mg / kg body weight rats of the pharmaceutical composition of embodiment 1-4 and comparative example 1-3, and the blank group and model group were gavaged with equal volume of normal saline, and 1 hour after gavage, except for the blank group, the rest of the groups were subcutaneously injected with 2,4-dinitrophenol 15mg / kg in the back, and the fever model group had a body temperature rise of 0.8℃, which was a successful modeling. The body temperature of each group was measured every 1 hour, and the measurement was continuously measured for 3 hours, and the body temperature change data of each group of rats was measured and counted, and the results are shown in the following table.

[0074] Table 1 Effects of each group of drugs on body temperature of rats

[0075] Group 0h 1h 2h 3h Blank group 37.5±1.2 <![CDATA[37.5±1.4 a ]]> <![CDATA[37.2±1.6 a ]]> <![CDATA[37.1±0.9 a ]]> Model Group 37.6±1.1 <![CDATA[40.4±2.6 b ]]> <![CDATA[39.6±2.3 b ]]> <![CDATA[39.0±2.2 b ]]> Example 1 Group 37.6±1.5 <![CDATA[38.9±1.8 c ]]> <![CDATA[38.1±1.0 c ]]> <![CDATA[37.6±1.3 a ]]> Example 2 Group 37.7±1.6 <![CDATA[39.3±1.9 b ]]> <![CDATA[38.6±2.0 c ]]> <![CDATA[38.0±1.5 a ]]> Example 3 Group 37.4±1.4 <![CDATA[38.8±1.6 c ]]> <![CDATA[38.2±1.3 c ]]> <![CDATA[37.7±1.7 a ]]> Example 4 Group 37.7±2.0 <![CDATA[39.2±2.0 b ]]> <![CDATA[38.6±1.9 c ]]> <![CDATA[37.9±1.1 a ]]> Comparative Example 1 37.5±1.4 <![CDATA[39.8±2.4 b ]]> <![CDATA[39.1±2.1 b ]]> <![CDATA[38.8±1.6 b ]]> Comparative Example 2 37.6±1.7 <![CDATA[39.7±2.3 b ]]> <![CDATA[38.9±2.4 b ]]> <![CDATA[38.4±1.2 b ]]> Comparative Example 3 37.2±1.3 <![CDATA[39.5±2.5 b ]]> <![CDATA[39.0±2.2 b ]]> <![CDATA[38.5±2.5 b ]]>

[0076] Note: Different letters in each column indicate P < 0.05.

[0077] According to the results in Table 1, the pharmaceutical compositions of Examples 1-4 of the present invention can significantly relieve fever caused by 2,4-dinitrophenol, and have a better therapeutic effect when the mass ratio of scutellaria baicalensis, scutellaria baicalensis and acetaminophen is 25-33:32-38:2. In addition, the rats in Groups 1-4 of Examples of the present invention did not show drowsiness and loss of appetite during the treatment period compared with the other groups.

[0078] Effect Example 2 Study on the therapeutic effect of the drug composition on influenza virus

[0079] ICR mice (purchased from the Model Animal Institute of Nanjing University) weighing 14 g ± 1 g, half male and half female, were used. The influenza A1 virus FM1 strain (provided by the National Institute for the Control of Pharmaceutical Biologicals) was used, and after the virulence was enhanced in mice, it was passaged twice in the allantoic cavity of chicken embryos.

[0080] The modeling and drug administration methods are as follows:

[0081] (1) Virus dilution: Dissolve the virus seed in water and dilute with sterile saline to a concentration of 15 LD per 0.05 mL. 50 , store in ice water.

[0082] (2) Infected mice: The mice were randomly divided into 9 groups, namely, a normal group, a model group, Example 1-4 groups, and Comparative Example 1-3 groups, with 10 mice in each group. The normal group was not treated, and the mice in the other 8 groups were anesthetized and 4 drops of virus solution were dripped into the nose.

[0083] (3) Administration: The normal group and the model group were intragastrically administered with distilled water, and the Example 1-4 and the Comparative Example 1-3 groups were intragastrically administered with the pharmaceutical composition of Example 1-4 and the pharmaceutical composition of the Comparative Example 1-3 groups at 0.15 g / kg of mouse body weight each time, twice a day for 4 consecutive days.

[0084] (4) Determination of lung index: Four days after infection, mice were killed and dissected. They were fasted and deprived of water for more than 4 hours before being killed and dissected. The mice were weighed and their lungs were removed after being killed. The lungs were washed twice in a flat dish containing 0.9% saline. The surface moisture was blotted with absorbent paper and the lung weight was weighed. The lung index and inhibition rate were calculated according to the following formula: lung index = mouse lung weight / mouse weight; lung index inhibition rate = (average lung index of the model group - average lung index of the drug group) / average lung index of the model group × 100%. The specific results are shown in the following table.

[0085] Table 2 Results of the inhibitory effects of each group of drugs on pneumonia in mice infected with influenza virus

[0086]

[0087]

[0088] Note: Different letters in each column indicate P < 0.05.

[0089] According to the results in the above table, compared with the blank group, the lung index of the model group increased significantly, indicating that the modeling was successful. Compared with the model group, the pharmaceutical composition of the present invention has a significant inhibitory effect on pneumonia, and when the mass ratio of scutellaria baicalensis, scutellaria baicalensis and acetaminophen is 25-33:32-38:2, it has a better therapeutic effect; during the treatment period, the mice in Example 1-4 groups did not show drowsiness and loss of appetite, indicating that the pharmaceutical composition of the present invention has a significant therapeutic effect on the treatment of influenza virus and does not produce side effects.

[0090] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.

Claims

1. A pharmaceutical composition for treating a cold, characterized in that: The invention is prepared from the following raw materials by weight: 10-20 parts of acetaminophen, 0.5-0.9 parts of loratadine, 240-330 parts of physalis, 320-420 parts of chelidonium and 100-150 parts of xanthium; The mass ratio of the herb, physalis scabra and acetaminophen is 25-33:32-38:

2.

2. The pharmaceutical composition according to claim 1, characterized in that: The invention is prepared from the following raw materials: 10-20 parts of acetaminophen, 0.5-0.8 parts of loratadine, 280-330 parts of phytoncidum, 320-350 parts of chelidonium and 100-120 parts of xanthium.

3. The pharmaceutical composition according to claim 2, characterized in that: The invention is prepared from the following raw materials by weight: 20 parts of acetaminophen, 0.8 parts of loratadine, 280 parts of phytoncides, 320 parts of chelidonium and 100 parts of xanthium.

4. A method for preparing the pharmaceutical composition according to any one of claims 1 to 3, characterized in that: The following steps are involved: S1, taking the formulated amount of Herba Lycopodii, Herba Lycopodii and Herba Xanthium, adding 1,3-butanediol, adjusting the pH, performing ultrasonic extraction, then filtering, and removing 1,3-butanediol by rotary evaporation to obtain an alcohol extract; S2, adding ultrapure water to the alcohol-extracted physalis, physalis scabra and Xanthium sibiricum for ultrasonic extraction, and then filtering to obtain a water extract; S3, combining the alcohol extract and the water extract, concentrating under reduced pressure to obtain a concentrate, and freeze-drying to obtain a Chinese medicine powder; S4. Then, the acetaminophen and loratadine in the formula amount are crushed separately and then mixed, and the above-mentioned Chinese medicine powder is added and mixed evenly to obtain a pharmaceutical composition.

5. The preparation method according to claim 4, characterized in that: In step S1, the material-liquid ratio of the total mass of the Herba Lycopodii, Herba Eupatorii and Herba Xanthium to 1,3-butanediol is 1 g: 5-8 ml; the concentration of the 1,3-butanediol is 70%-80%.

6. The preparation method according to claim 4, characterized in that: The pH in step S1 is 4-6; the conditions for ultrasonic extraction in step S1 are: temperature 40-45° C., extraction times 1-3 times, and each ultrasonic extraction time 5-8 min.

7. The preparation method according to claim 4, characterized in that: In step S2, the total mass of the phytoncides, phytoncides and Xanthium sibiricum after alcohol extraction and the material-liquid ratio of ultrapure water is 1g:8-10ml.

8. The preparation method according to claim 4, characterized in that: The conditions for ultrasonic extraction in step S2 are: temperature 20-25° C., time 10-15 min.

9. Use of the pharmaceutical composition according to any one of claims 1 to 3 or the pharmaceutical composition prepared by the preparation method according to any one of claims 4 to 8 in preparing medicines for treating colds.

Images